Eisai Inc. clinical trial failures

Review 35 stopped clinical trials from Eisai Inc., including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 3 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials35

Likely biological signals3

Shown below35

Dominant stop reasons

OPERATIONAL: 16
OTHER/UNKNOWN: 16
EFFICACY/FUTILITY: 2
SAFETY: 1

Notable sponsors

Eisai Inc.: 35

Related phases

Phase I: 13
Phase II: 11
Phase III: 8
Phase IV: 3

Crawlable stopped-trial records

Open Explore

Showing up to 35 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04572243: A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Phase III Epilepsies, Myoclonic trial by Eisai Inc.. Stop reason: OPERATIONAL.

The study was terminated by Sponsor and the decision was not due to any safety or efficacy reasons.

NCT01127178: Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Phase I Solid Tumors trial by Eisai Inc.. Stop reason: OPERATIONAL.

Strategic decision, which is unrelated to safety

NCT04144140: Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Phase I Lymphoma trial by Eisai Inc.. Stop reason: OPERATIONAL.

The study was terminated earlier due to a business decision; which was unrelated to safety. In addition, there was no clinical activity data that informed the decision.

NCT01133990: FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase I Colorectal Cancer trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not tolerable, hence no efficacy analysis was conducted.

NCT01133756: E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Phase I Ovarian Cancer trial by Eisai Inc.. Stop reason: OPERATIONAL.

poor accrual

NCT01347645: Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Phase I Colon Cancer trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

The study was terminated by the Sponsor due to E7820 plus irinotecan being potentially inferior to FOLFIRI

NCT00209599: A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy

Phase II Colonoscopy trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT00209586: A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy

Phase III Flexible Bronchoscopy trial by Eisai Inc.. Stop reason: OPERATIONAL.

Patient enrollment was stopped prior to completion of the study in order to re-evaluate the dosing regimen.

NCT01177540: Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Phase II Pediatric Acute Myelogenous Leukemia (AML) trial by Eisai Inc.. Stop reason: EFFICACY/FUTILITY.

The study was terminated early due to enrollment difficulties and the futility of observing differences in remission rate between treatment arms.

NCT03603639: A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy

Phase II Photosensitive Epilepsy trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

The study was stopped due to efficacy reasons.

NCT02834793: Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Phase III Lennox-Gastaut Syndrome (LGS) trial by Eisai Inc.. Stop reason: OPERATIONAL.

Sponsor's decision

NCT01126749: Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Phase I Bladder Cancer trial by Eisai Inc.. Stop reason: OPERATIONAL.

Study was terminated as per sponsor's decision

NCT03338296: Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Phase IV Obesity trial by Eisai Inc.. Stop reason: OPERATIONAL.

Study was terminated as Eisai agreed to voluntarily withdraw Belviq XR from US market.

NCT01433991: A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Phase I Advanced Solid Tumors trial by Eisai Inc.. Stop reason: OPERATIONAL.

Study was terminated by the sponsor early at the end of Phase 1b due to a change in corporate strategy.

NCT00675025: Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

Phase II Down Syndrome trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.

NCT02322021: Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Phase II Alzheimer Disease trial by Eisai Inc.. Stop reason: SAFETY.

This study was terminated early by the sponsor on the recommendation of an independent data safety monitoring board following review of unblinded data from the Phase 3 studies E2609-G000-301 (NCT02956486) and E2609-G000-302 (NCT03036280).

NCT04109092: A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Phase I Urinary Bladder Neoplasms trial by Eisai Inc.. Stop reason: OPERATIONAL.

There was no enrolment of participants.Unscheduled Clinical Study Closure - Eisai Network Company Decision, November 12, 2020.

NCT03686033: A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

Phase II Photosensitive Epilepsy trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

Safety Review

NCT02753595: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase I Metastatic Breast Cancer trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

evolving standard of care and difficulties of enrolling participants

NCT02540291: Study of E7046 in Subjects With Selected Advanced Malignancies

Phase I Tumors trial by Eisai Inc.. Stop reason: OPERATIONAL.

Terminated due to, licensing agreement granting exclusive rights of research, development, manufacture and marketing of Eisai's E7046 to Adlai Nortye Biopharma.

NCT00754013: Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

Phase III Down Syndrome trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

Sufficient evidence of efficacy not met.

NCT03433703: Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Phase II Carcinoma, Hepatocellular trial by Eisai Inc.. Stop reason: OPERATIONAL.

Study recruitment was stopped due to difficulty in enrolling the targeted number of participants.

NCT00448539: Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Phase III Refractory Partial Onset Seizures trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

The study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.

NCT02657369: A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Phase II Thyroid Carcinoma, Anaplastic trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

Overall response rate was 3% (only 1 out of 33 participants had confirmed PR).

NCT00566462: Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

Phase II Parkinson's Disease trial by Eisai Inc.. Stop reason: EFFICACY/FUTILITY.

Study stopped due to lack of efficacy.

NCT00754052: Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Phase III Down Syndrome trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.

NCT01433978: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Phase III Idiopathic Thrombocytopenic Purpura trial by Eisai Inc.. Stop reason: OPERATIONAL.

Study was terminated early due to significant enrollment challenges.

NCT00474409: A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

Phase IV Vertigo trial by Eisai Inc.. Stop reason: OPERATIONAL.

Due to poor enrollment, this study was withdrawn/ terminated.

NCT01355302: E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Phase I Advanced or Metastatic Solid Tumors trial by Eisai Inc.. Stop reason: OPERATIONAL.

Sites not recruiting

NCT01605162: Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Phase II Wild Type BRAF Stage IV Melanoma trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT02249078: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease

Phase I Crohn's Disease trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT00282399: A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

Phase I Myelodysplastic Syndrome trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT00943553: A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Phase II Acute Myelogenous Leukemia (AML) trial by Eisai Inc.. Stop reason: OPERATIONAL.

Terminated by Sponsor

NCT02220972: To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures

Phase IV Epilepsy, Partial trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT00209560: A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures

Phase III Arthroscopy trial by Eisai Inc.. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.